Somerset, NJ – According to filings with the U.S. Securities and Exchange Commission, Legend Biotech is raising $160,450,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Yuan Xu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Legend Biotech

At Legend Biotech from the very beginning, we’ve been focused on the science. We came together as a team of experts, committed to quality, driven by excellence, and dedicated to experimentation. Though we faced many challenges, we remained fearless in our research and rigorous in our thinking, pushing ourselves to work harder. But what impacted us the most was the enormous burden patients bear and the difficulties they face, which drove us to think about what’s next. We believe it’s time to accelerate and expand that transformation. At Legend Biotech, we are excited to bring clinical trials to patients in our pursuit of a cure. While we are focused on CAR-T in multiple myeloma, we firmly believe the prospects of cellular therapy stretch beyond just one disease or indication.  

To learn more about Legend Biotech, visit http://www.legendbiotech.com/

Contact:
Yuan Xu, Chief Executive Officer
732-317-5050
https://www.linkedin.com/in/yuanxubiologics/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved